• Fulcrum Therapeutics director Alan Ezekowitz sold 18,000 common shares on June 26, 2026.
• Shares sold at a weighted average price of $3.65.
• Ezekowitz held 10,927 shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-290622), on June 30, 2026, and is solely responsible for the information contained therein.